PCL Alverno Laboratories Launches Blood Test to Aid in the Early Detection of Lung Cancer
PCL Alverno Laboratories Introduces Oncimmune´s EarlyCDT®-Lung, a Blood Test to Aid in Risk Assessment and the Early Detection of Lung Cancer
(PRWEB) March 19, 2013
PCL Alverno announced today that it has recently entered into an agreement with Oncimmune® USA LLC to offer EarlyCDT®-Lung to their extensive physician base in the Midwest. EarlyCDT-Lung is an innovative blood test that aids in the risk assessment and the early detection of lung cancer.
“Oncimmune is excited to add PCL ALVERNO as a partner to offer EarlyCDT-Lung test to their physicians,” said Greg Stanley, Chief Commercial Officer at Oncimmune USA. “We believe that through this relationship with PCL ALVERNO and our growing base of partners in the US, we can improve the outlook and well-being for countless individuals who are at increased risk for developing lung cancer.”
Lung cancer is the primary cause of cancer deaths amongst men and women in the United States, killing more people each year than breast, colon, prostate, liver, kidney and melanoma combined. 85% of newly diagnosed cases of lung cancer are found symptomatically and most often at late stages; the 5-year survival rate can be as low as 4% in later stage lung cancer. In 2012, over 226,000 new cases of lung cancer were diagnosed and over 160,000 perished from the disease.
The performance and clinical utility of EarlyCDT-Lung test is supported by 17 peer-reviewed publications, click here. The test has a high specificity (93%), seven times fewer false positives and seven times better positive predictive value (PPV) than CT. Additionally, the test offers >91% accuracy, when considering a population with 2% prevalence of lung cancer (20 lung cancers per thousand).
Currently, numerous leading academic institutions, as well as more than 2,000 physicians throughout the United States are offering the test. A prospective audit of clinical data from the first 1,600 patients tested by EarlyCDT-Lung validates its utility to detect early-stage lung cancer and its overall performance, click here. Additionally, the Scottish government is conducting a 10,000-patient randomized clinical trial to validate the economic benefit of the test in screening high-risk patients, click here.
Patient blood samples sent to PCL ALVERNO will be analyzed at Oncimmune´s CLIA-certified laboratory located in De Soto, Kansas.
About PCL ALVERNO
PCL Alverno is a full service, community based medical laboratory performing over 750 tests in both clinical and anatomic pathology.
PCL Alverno’s innovative, state-of-the-art laboratory is the only free-standing, local reference lab in its service area. PCL Alverno offers the convenience and personal customer service of a local laboratory with the sophistication of a large reference laboratory.
Our team of onsite pathologists, along with our excellent staff, are committed to serve you. PCL Alverno’s pathologists are part of the pathology practice of Pathology Consultants, Inc. PCL Alverno is located at 2434 Interstate Plaza Drive, Hammond, IN 46324. You can reach us at 800-937-5521
Oncimmune is a privately funded company located in Nottingham, UK with US headquarters and a CLIA laboratory located just outside of Kansas City. The company launched a proprietary platform technology for early cancer detection, called EarlyCDT®. The first commercially available test, EarlyCDT®-Lung, a blood test to aid in the early detection and risk assessment of lung cancer, was released in 2009. The EarlyCDT® platform technology measures autoantibodies (immuno-biomarkers) in blood that form early in carcinogenesis. When the body recognizes something as “non-self,” one of the ways it responds is for the immune system to produce large amounts of antibodies. The immune system does not normally produce antibodies against normal tissue proteins and therefore these immuno-biomarkers to cancer antigens provide high specificity for cancer.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/3/prweb10525235.htm